Preclinical data suggest that montelukast may suppress tumor growth through two potential mechanisms: firstly, by antagonizing CysLT1-R signaling pathways involved in tumor proliferation, survival, and inflammatory signaling—independent of mutational background6; and secondly, by modulating or indirectly antagonizing CysLT2-R expression, which may be particularly relevant in CYSLTR2-mutant tumors.10 This evidence concerns the gene CYSLTR2 and neoplasm.